Marinus pharmaceuticals inc.

Marinus Pharmaceuticals last issued its quarterly earnings data on November 7th, 2023. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.06. The firm had revenue of $7.34 million for the quarter, compared to analyst estimates of $6.54 million.Jan 30, 2023 · About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY ® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder ... Aug 10, 2023 · Marinus to host conference call on August 10, 2023, at 8:30 a.m. ET RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June ... Sasha Damouni Ellis Vice President, Corporate Affairs & Investor Relations Marinus Pharmaceuticals, Inc. 484-253-6792 [email protected] Release Summary

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disordMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Website http://www.marinuspharma.com Industry...

Jun 8, 2022 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has amended the protocol for its Phase 3 RAISE trial in refractory status epilepticus (RSE) to expand eligibility criteria, support patient recruitment and drive enrollment efficiencies ...

Age: 54. Gender: M. Sivasankaran is a IND candidate from Ozhukarai constituency in the 2021 Puducherry Assembly elections. His profession according to the …Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.Hayward Pool Products Inc. is a leading manufacturer and distributor of swimming pool equipment and supplies. With over 80 years of experience, the company has been at the forefront of innovation in the swimming pool industry.Effective Date: March 18, 2022. Marinus Pharmaceuticals, Inc. (“Marinus”, “we”, us” or “our”) is committed to protecting the privacy and security of your ...

RADNOR, Pa., October 24, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today ...

Marinus Pharmaceuticals Inc (Marinus Pharmaceuticals) is a biopharmaceutical company. It discovers, develops and commercializes therapies for the treatment of rare …

You may also contact Marinus Pharmaceuticals at 844-627-4687. For additional information, please click here for Medication Guide and Instructions for Use and discuss with your doctor.RADNOR, Pa.-- ( Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ...Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is ...Marinus Pharmaceuticals stock opened at $7.50 on Tuesday. The company has a debt-to-equity ratio of 1.79, a current ratio of 6.38 and a quick ratio of 6.29. The …Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Marinus to host conference call today at 4:05 p.m. ET RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March …Feb 13, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will host a conference ... Dec 7, 2020 · Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a neuroactive steroid GABA ...Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results. RADNOR, Pa., November 07, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial …

RADNOR, Pa., March 07, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today ...

Sasha Damouni Ellis Vice President, Corporate Affairs & Investor Relations Marinus Pharmaceuticals, Inc. 484-253-6792 [email protected] Release SummaryRADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a collaboration and supply agreement with Tenacia Biotechnology (Shanghai) Co., Ltd., a …14 Nov 2023 ... Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company ...22 Sept 2022 ... The U.S. government has exercised a $12.3 million option with Marinus Pharmaceuticals to manufacture the active pharmaceutical ingredient ...Jul 14, 2022 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.RADNOR, Pa.-- ( Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ...About Marinus Pharmaceuticals reformulates, develops, and commercializes drugs to treat neurological, psychiatric, and pain disorders. Branford, Connecticut, United States 101-250 Post-IPO Equity Public www.marinuspharma.com 6,550 Highlights Stock Symbol NASDAQ:MRNS Total Funding Amount Unlock for free Contacts 117 Employee Profiles 9 Investors 8Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants restricted Stock Units (the “RSUs”) representing the right to receive shares of its common stock, par value $0.001 (the “Stock”), to the recipient (the “Grantee”) set forth on the Schedule to Restricted Stock Unit Agreement attached hereto (the “Schedule”), …November 07, 2023 at 07:38 am EST. RADNOR, Pa. (AP) — RADNOR, Pa. (AP) — Marinus Pharmaceuticals Inc. (MRNS) on Tuesday reported a loss of $33 million in its third quarter. The Radnor, Pennsylvania -based company said it had a loss of 61 cents per share. The results exceeded Wall Street expectations.

Effective Date: March 18, 2022. Marinus Pharmaceuticals, Inc. (“Marinus”, “we”, us” or “our”) is committed to protecting the privacy and security of your ...

Doing Business As: Marinus Pharmaceuticals Company Description: Marinus Pharmaceuticals is ready to put an end to epileptic seizures. The biopharmaceutical company is developing a drug candidate, ganaxolone, to be used as an add-on therapy for the treatment of partial onset seizures in people with epilepsy.

Item 8.01. Other Events. On November 28, 2023, Marinus Pharmaceuticals, Inc. posted an updated corporate presentation on its website at www.marinuspharma.com. A copy of the corporate presentation is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Item 9.01.RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a collaboration and supply agreement with Tenacia Biotechnology (Shanghai) Co., Ltd., a …Apr 12, 2021 · Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. May 11, 2023 · RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023. RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) …Marinus Pharmaceuticals has 5 employees at their 1 location and $25.48 m in annual revenue in FY 2022. See insights on Marinus Pharmaceuticals including …RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.“This year has already …Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.Marinus Pharmaceuticals to Present at Upcoming Investor Conferences. May 3, 2023. Download. RADNOR, Pa.-- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during ...About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a ...About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY ® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder ...

Marinus Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 7.34 million compared to USD 2.34 million a year ago.Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial ...A company with a name that ends in “inc.” is incorporated, giving its owners, officers and investors specific legal advantages. Essentially, these key people in the business have no personal liability in the event that the business fails or...Instagram:https://instagram. ap stockbuying and trading cryptocurrencyplymfutures trading platforms for mac RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will host a conference ...Effective Date: March 18, 2022. Marinus Pharmaceuticals, Inc. (“Marinus”, “we”, us” or “our”) is committed to protecting the privacy and security of your ... how much is the copper in a penny worthoark etf RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Marinus … best loans for investment properties Jan 30, 2023 · About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY ® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder ... Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of therapeutics for seizure disorders. The Company's commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the United States Food and Drug Administration (FDA) for the …